Immunological Effects Of Minimally Invasive Therapies In Patients With Hepatocellular Carcinoma

Immunological Effects Of Minimally Invasive Therapies In Patients With Hepatocellular Carcinoma - ImmuMITT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026994

Enrollment

128

Registered

2021-12-07

Start date

2020-06-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Transarterial Chemoembolization (TACE) Group 2: High-dose rate brachytherapy in Afterloading technique (HDRBT) Group 3: Transarterial Chemoembolization in combination with high-dose rate brac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-resectable HCC with tumor board reviewed recommendation for minimally-invasive therapies including TACE and HDRBT

Exclusion criteria

Exclusion criteria: other malignancies of the liver excluding HCC

Design outcomes

Primary

Measure	Time frame
Treatment response - measured by standardized, image morphological criteria such as (m)RECIST or LIRADS-TRA v2017at defined time points (after 2 months, after 5 months, and subsequently every 3-6 months post-intervention).	—

Secondary

Measure	Time frame
Overall survival, Progression-free survival - measured by reporting data from the hospital's own documentation system as well as national cancer registries and, if applicable, registration offices.	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026